RET and metastatic neoplasm: In a recent study involving 58 sporadic MTCs (40 with somatic RET mutation and 10 with somatic RAS mutation), CDKN2C loss correlated with shorter time to distant metastatic disease (1.59 years vs. 5.18 years, p = 0.03) while RET mutations did not reach significance (2.83 years vs. 6.60 years, p = 0.5) [79].